Cargando…
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
Metastatic melanoma is characterized by a poor response to chemotherapy. Furthermore, there is a lack of established predictive and prognostic markers. In this single institution study, we correlated mutation status and expression levels of BRAF and NRAS to dacarbazine (DTIC) treatment response as w...
Autores principales: | Birkeland, Einar, Busch, Christian, Berge, Elisabet Ognedal, Geisler, Jürgen, Jönsson, Göran, Lillehaug, Johan Richard, Knappskog, Stian, Lønning, Per Eystein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837233/ https://www.ncbi.nlm.nih.gov/pubmed/23673558 http://dx.doi.org/10.1007/s10585-013-9587-4 |
Ejemplares similares
-
Alterations of the retinoblastoma gene in metastatic breast cancer
por: Berge, Elisabet Ognedal, et al.
Publicado: (2011) -
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
por: Berge, Elisabet Ognedal, et al.
Publicado: (2010) -
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
por: Løes, Inger Marie, et al.
Publicado: (2014) -
Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007) -
MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2015)